Medilumine is pleased to announce a new distribution partnership with NanoPET Pharma through its Viscover brand. Medilumine is now an authorized distributor of the full Viscover platform for in vivo preclinical imaging including:
MicroCT Contrast Agents
MRI Contrast Agents
Fluorescent Contrast Agents
Ultrasound Contrast Agents
This partnership expands access to well established contrast agents that support detailed soft tissue and vascular imaging beyond conventional skeletal CT.
Viscover ExiTron agents are widely used in preclinical research to enable high contrast visualization of vascular networks, organs, and disease related changes in tissue perfusion and structure. Their nanoparticle based formulation allows for prolonged circulation and uptake in target tissues, making them suitable for applications such as angiography, organ perfusion studies, tumor vascularization analysis, and longitudinal imaging in small animal models.
Through this partnership, Medilumine provides direct and authorized access to NanoPET Pharma reagents along with scientific and application level support. Researchers can obtain guidance on selecting appropriate contrast agents for their animal models and imaging platforms, including integration into multimodal workflows that combine micro CT with optical, fluorescence, or other imaging techniques. Medilumine also offers a reliable supply chain and transparent ordering process to support reproducible and time sensitive studies.
The ExiTron product family includes agents optimized for different biological and imaging needs. ExiTron nano 12000 is designed for high resolution vascular imaging and liver tumor detection, enabling detailed visualization of blood vessels and pathological neovascularization. ExiTron nano 6000 provides liver specific uptake and is suitable for longitudinal organ imaging where stable contrast over time is required. Additional ExiTron variants are available to support diverse preclinical applications across oncology, cardiovascular research, inflammation, and organ function studies.
By combining Viscover contrast agents with Medilumine’s expertise in preclinical imaging workflows, researchers gain access to both validated reagents and technical support that facilitates quantitative and reproducible micro CT studies. This partnership is intended to streamline the process of reagent selection, experimental design, and imaging execution for laboratories working in translational and discovery research.
Medilumine offers the Viscover™ portfolio of preclinical MRI contrast agents, designed to enhance image quality and expand the capabilities of animal MRI studies. The portfolio includes GadoSpin™ gadolinium chelates for high-performance vascular, organ, and tumor imaging, and FeraSpin™ iron oxide nanoparticles, which are widely used for cell labeling and in vivo cell tracking by MRI. Together, Viscover MRI agents support applications such as cell tracking, tumor and vascular imaging, cardiovascular studies, magnetic resonance angiography (MRA), and therapy response monitoring, enabling more informative and translational preclinical imaging.
Viscover NiraWave agents are advanced fluorescent imaging reagents widely used in preclinical research to study vascular structures, inflammation, and tumor biology. Their nanoparticulate and micellar formulations provide high fluorescence intensity, prolonged circulation, and excellent tissue penetration, enabling detailed visualization of blood vessels, vascular leakage, and tumor progression in small animal models.
Through this partnership, MediLumine offers authorized access to NiraWave reagents along with scientific guidance and application support. Researchers can receive assistance in selecting the optimal agent for their animal models and imaging systems, including integration into multimodal workflows that combine fluorescent imaging with CT, MRI, or ultrasound. MediLumine ensures a reliable supply chain and transparent ordering to support reproducible and time-sensitive studies.
The NiraWave product family includes agents optimized for different imaging needs:
Optical image of a TNCB-induced CHS mouse 10 min after injection of NiraWave M.
The image reveals an enhanced fluorescence signal in the right inflamed ear tissue compared to the left control ear due to elevated perfusion and vascular leakage.
By combining NiraWave agents with MediLumine’s expertise in preclinical imaging workflows, researchers gain access to validated reagents and technical support that enable quantitative, reproducible fluorescent imaging studies. This approach streamlines contrast agent selection, experimental design, and imaging execution for translational and discovery research.
Viscover PolySon agents are widely used in preclinical research to enable highly sensitive and quantitative visualization of organ perfusion, tumor vascularization, and microvascular structures. Their micrometer-sized, hard-shell polymeric microbubble formulation provides exceptional echogenicity and stability, allowing both conventional ultrasound imaging and advanced single-bubble quantification techniques such as stimulated acoustic emission (SAE). These features make PolySon agents suitable for applications including organ perfusion studies, tumor imaging, and longitudinal vascular research in small animal models.
Through this partnership, MediLumine provides direct and authorized access to Viscover PolySon reagents, along with scientific guidance and application support. Researchers can receive advice on selecting the most appropriate contrast agent for their animal models and imaging setups, including integration into multimodal workflows combining ultrasound with optical, CT, or MRI techniques. MediLumine also ensures a reliable supply chain and streamlined ordering to support reproducible and time-sensitive studies.
The PolySon product family includes agents optimized for different imaging requirements:
Cardiac perfusion in mouse using PolySon L. The three frames from the video clip show the filling of the heart with contrast agent in green false-color.
By combining Viscover PolySon agents with MediLumine’s expertise in preclinical imaging workflows, researchers gain access to validated reagents and technical support that facilitates reproducible, quantitative ultrasound studies. This partnership streamlines the process of contrast agent selection, experimental design, and imaging execution for laboratories engaged in translational and discovery research.
For further information on ExiTron products, technical documentation, or assistance in selecting the most appropriate contrast agent for your study, please contact the Medilumine team.
Almost all animals with functional vision exhibit a variety of eye movements. These movements allow compensation for shifts in the visual scene and enable tracking
Medilumine is pleased to announce a new distribution partnership with NanoPET Pharma through its Viscover brand. Medilumine is now an authorized distributor of the full
